# MAIA Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maia-biotechnology

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.maiabiotech.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Oct 9, 2019)
- Investors on record: 1

## About

MAIA Biotechnology, Inc. is a Chicago-based firm specializing in the development of novel telomere-targeting immunotherapies aimed at combatting cancer by enhancing the immune response against tumors.Founded in 2018 and headquartered in Chicago, US, MAIA Biotechnology, Inc. focuses on innovative cancer therapies. The company has completed 4 funding deals with its latest round occurring on March 16, 2022, where it raised USD 2.4 mn. The founder, Vlad Vitoc, serves as the CEO and has been instrumental in the company's strategic direction.MAIA Biotechnology specializes in telomere-targeting immunotherapies designed to treat various forms of cancer. Their flagship product, Ateganosine (THIO), is in clinical trials and aims to enhance immune responses against cancer cells. The company primarily targets oncologists and healthcare providers in North America and Europe, providing solutions for hospitals, research institutions, and specialized cancer treatment centers.MAIA Biotechnology generates revenue through strategic partnerships and collaborations within the biotechnology sector, including licensing deals and milestone payments related to drug development phases. Their innovative therapies, such as Ateganosine, are structured to align with pricing plans reflecting the value delivered to healthcare providers and patients, although specific pricing details are not disclosed.MAIA Biotechnology plans to utilize the USD 2.4 mn raised in March 2022 to advance its clinical programs, specifically focusing on initiating Phase 2 clinical trials (THIO-101) for the administration of THIO followed by cemiplimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The company aims to expand its presence in existing markets while exploring additional opportunities in other regions with robust cancer treatment needs.

## Funding rounds

- Seed, Oct 9, 2019, $1.5M — KIZOO Technology Ventures

## Investors

- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed